Scientific deep-dive

Beyond the Scale: Blood Pressure, Lipids and What Else Changes

Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo, and by about the same amount whether or not the person had hypertension.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·3 citations

The scale is the thing everyone watches, but it is not the only thing that moves. Pooling the individual records of 3,136 people across three semaglutide trials, systolic blood pressure fell 4.95 mmHg further than on placebo.[1] The surprise is in the subgroups: that reduction was roughly the same whether or not someone had hypertension to begin with, which is not what the researchers expected to find.

Why this analysis is worth more than most

Most meta-analyses pool published summaries, the averages each trial reported. An individual patient data meta-analysis goes back to the per-person records and re-analyses them together, which allows questions the original papers never asked. That is what happened here, across three randomized trials of semaglutide 2.4 mg run over 68 weeks.[1]

The question they wanted to answer was a sensible one. Blood pressure drugs generally work harder in people whose pressure is higher, so if semaglutide lowers pressure you would expect a bigger effect in people with hypertension. They split the participants four ways to look.

Systolic blood pressure difference against placebo, by baseline category. Individual patient data from three trials, 3,136 participants.
GroupDifference (mmHg)95% CI
Everyone−4.95−5.86 to −4.05
Diagnosed or treated hypertension−4.78−5.97 to −3.59
Baseline systolic above 130−4.93−6.75 to −3.11
Baseline systolic above 140−4.09−7.12 to −1.06
Apparent resistant hypertension−3.16−8.69 to 2.37 (not significant)

The first three groups land between about four and five points, close to the overall figure. The fourth, people with apparent resistant hypertension, came in at 3.16 points, and that interval crosses zero, so the result is not statistically significant. A drug that lowers blood pressure by a similar amount whether or not yours is high is behaving unlike an antihypertensive and more like something changing the underlying state.

Five points is not nothing and it is not a cure. It is roughly the order of a single low-dose blood pressure medicine. This analysis measured the pressure reading, not heart attacks or strokes, and the same limit applies to the tirzepatide and 24-hour readings. Those come from separate trials with separate endpoints. Do not let anyone convert a millimeter of mercury into a promise about your heart.

Cholesterol, blood sugar and the rest

The broadest comparison available is a network meta-analysis of 76 trials covering 15 different GLP-1 drugs and 39,246 participants with type 2 diabetes, looking at glycemic control, weight and lipid profile together.[2] All fifteen lowered HbA1c against placebo. Tirzepatide came out strongest on glycemic control. LDL cholesterol barely moves: semaglutide, the drug the review singles out on lipids, lowered it by 0.16 mmol/L against placebo.[2] That is one reason these drugs are not a fix for yellow eyelid plaques (see xanthelasma and weight loss).

A network meta-analysis is how you compare drugs that were never tested against each other, by chaining through their common comparators. It is a legitimate and useful method, but it is weaker than a head-to-head trial, because the chain inherits every difference between the trial populations it links.

The list is longer than it used to be

A 2026 review in the Lancet Diabetes & Endocrinology takes the widest view yet, framing obesity as a gateway condition and gathering the trial evidence across the systems it drives.[3] The conditions it works through include type 2 diabetes, fatty liver disease, chronic kidney disease, heart failure, cardiovascular disease, sleep apnea, polycystic ovary syndrome, osteoarthritis, muscle mass, depression, quality of life, food cravings, binge eating, substance use and neurodegenerative disease.

That breadth is striking, and it is also where care is required. A review covering fifteen conditions cannot give each the scrutiny a single-condition article can, and the strength of evidence differs enormously between them. A randomized trial in sleep apnea is not the same thing as an association in neurodegeneration.

  • Sleep apnea is an FDA-approved indication, with its own randomized trial.
  • PCOS has eleven trials, and two meta-analyses that disagree.
  • Substance use has an enormous cohort signal, and a randomized trial that missed.
  • Mood and suicidality is where the warning came off the label in February 2026.
  • Food cravings can be measured now, though the construct is contested.
  • Muscle mass loss looks different once it is compared with lifestyle weight loss.

What to do with any of this

If you take blood pressure medication and start a GLP-1, the pressure change is a reason for your prescriber to keep watching rather than a reason to adjust anything yourself. What the trials show about people coming off those medicines, and why dizziness is the signal to raise, is in dizziness and blood-pressure pills on a GLP-1. The blood-pressure analysis specifically tracked whether participants’ antihypertensive medications were changed during the trials, which is the kind of thing that has to be accounted for before a number like 4.95 means anything.[1]

Treat “beyond weight loss” claims with the skepticism the evidence deserves. On uric acid, two studies agreed the drugs lower it and disagreed on whether weight loss explains it. Some of these effects are established by randomized trials with hard endpoints. Others are associations in observational data, of the kind that have often failed to survive testing.

Frequently Asked Questions

Yes, by about five points systolic. An individual patient data meta-analysis of three semaglutide trials covering 3,136 people found a 4.95 mmHg greater fall than placebo. That is roughly the order of a single low-dose blood pressure medicine.
Apparently not, and that is the analysis's most interesting result. The reduction was about four to five points for people with diagnosed hypertension, people above 130 systolic and people above 140, close to the figure for everyone else. A subgroup with apparent resistant hypertension showed 3.16 points, which was not statistically significant. Blood pressure drugs usually work harder the higher the starting point, so this behaves differently.
A network meta-analysis of 76 trials covering 15 GLP-1 drugs and 39,246 people with type 2 diabetes examined lipid profile alongside glycemic control and weight. All fifteen lowered HbA1c against placebo, with tirzepatide strongest on glycemic control. The lipid effects were small; semaglutide lowered LDL cholesterol by 0.16 mmol/L against placebo. Network comparisons chain through common comparators rather than testing drugs head to head, which makes them useful and weaker than a direct trial.
No. That is a decision for the prescriber managing it. A falling reading on a new drug is a reason for closer monitoring, not for a unilateral change.
No, and the range matters. Sleep apnea has an FDA-approved indication supported by a randomized trial. Some of the other conditions on the list rest on observational associations, which have frequently failed to survive randomized testing. A long list is not a proven list.

References

  1. 1.Kennedy C, Hayes P, Cicero AFG, et al. Semaglutide and blood pressure: an individual patient data meta-analysis European Heart Journal. 2024. PMID: 39217502.
  2. 2.Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis BMJ. 2024. PMID: 38286487.
  3. 3.Savas M, Kuckuck S, Boon MR, van Rossum EFC. Beyond weight loss: multisystem benefits of obesity medications The Lancet Diabetes & Endocrinology. 2026. PMID: 42208956.

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read

Metformin and a GLP-1 Together: The Risk Is Not the One People Expect

The diabetes trials behind these drugs were largely run on people already taking metformin. Stomach side effects did not stack in the largest analysis, and low blood sugar comes from other drugs. The real overlap is dehydration.

8 min read

GLP-1 Drugs and Rheumatoid Arthritis: One Study, and What It Cannot Tell You

A retrospective review of 215 patients found greater falls in disease activity and pain among those who took a GLP-1 than among those prescribed one who did not. Nearly a third stopped the drug within the year.

6 min read

Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1

SGLT2 inhibitors like Jardiance and Farxiga are routinely taken with Ozempic or Mounjaro, and no label forbids it. Sugar and weight effects add up in trials; heart and kidney gains rest on subgroups. The real overlap is dehydration and ketoacidosis.

12 min read

GLP-1 Drugs in Cushing's Syndrome: Weight Down, Cortisol Unchanged

A multicenter retrospective study of 20 adults with Cushing's syndrome found weight down 10.3 kg and HbA1c down 0.5% over a median 13 months, with ACTH and cortisol levels stable throughout.

5 min read

Phentermine and a GLP-1 Together: What the Labels and Trials Show

Phentermine's label says combining it with any other weight-loss drug is not recommended; the Wegovy and Zepbound labels never mention it. The one trial, with liraglutide, found no meaningful extra loss. No semaglutide or tirzepatide trial exists.

10 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

9.1

Collective

From $69/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →